Literature DB >> 23324413

Palliative sedation: from the family perspective.

Petra Vayne-Bossert1, Gilbert B Zulian.   

Abstract

UNLABELLED: Palliative sedation (PS) is a treatment option in case of refractory symptoms at the end of life. The emotional impact on nurses and doctors has been widely studied. We explore the experience of family members during a PS procedure.
METHOD: An anonymous questionnaire was sent to the closest family members (n = 17) of patients who died while receiving palliative sedation.
RESULTS: The response rate was 59% (10 of 17). Nine relatives were sufficiently informed about PS. In all, 70% evaluated the chosen moment for initiation of PS as adequate. All the relatives noticed a significant improvement in the refractory symptom with a mean reduction in the estimated suffering of 6.25 points on a visual analog scale.
CONCLUSIONS: Palliative sedation should be performed in the best possible way for the patient and his family in order to efficiently reduce a refractory symptom.

Entities:  

Keywords:  emotional distress; family experience; information; palliative sedation; personal suffering; refractory symptom

Mesh:

Substances:

Year:  2013        PMID: 23324413     DOI: 10.1177/1049909112472930

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  3 in total

1.  Morally-Relevant Similarities and Differences Between Assisted Dying Practices in Paradigm and Non-Paradigm Circumstances: Could They Inform Regulatory Decisions?

Authors:  Jeffrey Kirby
Journal:  J Bioeth Inq       Date:  2017-10-05       Impact factor: 1.352

Review 2.  Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-05-01

3.  Palliative sedation for terminally ill cancer patients in a tertiary cancer center in Shanghai, China.

Authors:  Xiaoli Gu; Wenwu Cheng; Menglei Chen; Minghui Liu; Zhe Zhang
Journal:  BMC Palliat Care       Date:  2015-03-15       Impact factor: 3.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.